Lucid Diagnostics vs Neuraxis
Lucid Diagnostics is the larger business, with $4.7m of revenue in fiscal 2025 against $3.6m for Neuraxis (1.3 times as much). Neuraxis grew faster (32.9% against 8.3%). Neuraxis kept more of each dollar of sales as profit: a net margin of -218.5% against -1232.7%. Neuraxis carries less debt relative to equity (4.4% against 219.5%).
| Latest fiscal year | Lucid DiagnosticsLUCD, 2025 | NeuraxisNRXS, 2025 |
|---|---|---|
| Revenue | $4.7m | $3.6m |
| Revenue growth | 8.3% | 32.9% |
| Net income | −$58.0m | −$7.8m |
| Operating margin | -1054.8% | -219.4% |
| Net margin | -1232.7% | -218.5% |
| Return on equity | — | — |
| Free cash flow | −$46.7m | −$6.5m |
| Cash | — | $5.0m |
| Total debt | $24.0m | $148,293 |
| Debt to equity | 219.5% | 4.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 82 | 24 |
| Market value | $76.9m | $83.3m |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | — |
| Insider trades, 12 months | 1 buys, 0 sales | 9 buys, 0 sales |